- Home
- NUVL vs PEGA Comparison
NUVL vs PEGA Comparison
Compare NUVL & PEGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- PEGA
- Stock Information
- Founded
- NUVL 2017
- PEGA 1983
- Country
- NUVL United States
- PEGA United States
- Employees
- NUVL N/A
- PEGA N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- PEGA EDP Services
- Sector
- NUVL Health Care
- PEGA Technology
- Exchange
- NUVL Nasdaq
- PEGA Nasdaq
- Market Cap
- NUVL 6.7B
- PEGA 6.9B
- IPO Year
- NUVL 2021
- PEGA 1996
- Fundamental
- Price
- NUVL $87.30
- PEGA $96.46
- Analyst Decision
- NUVL Strong Buy
- PEGA Buy
- Analyst Count
- NUVL 10
- PEGA 10
- Target Price
- NUVL $112.60
- PEGA $85.90
- AVG Volume (30 Days)
- NUVL 350.8K
- PEGA 437.1K
- Earning Date
- NUVL 11-12-2024
- PEGA 02-12-2025
- Dividend Yield
- NUVL N/A
- PEGA 0.12%
- EPS Growth
- NUVL N/A
- PEGA N/A
- EPS
- NUVL N/A
- PEGA 1.36
- Revenue
- NUVL N/A
- PEGA $1,480,583,000.00
- Revenue This Year
- NUVL N/A
- PEGA $5.40
- Revenue Next Year
- NUVL N/A
- PEGA $7.09
- P/E Ratio
- NUVL N/A
- PEGA $70.77
- Revenue Growth
- NUVL N/A
- PEGA 9.28
- 52 Week Low
- NUVL $61.80
- PEGA $44.07
- 52 Week High
- NUVL $113.51
- PEGA $97.94
- Technical
- Relative Strength Index (RSI)
- NUVL 36.14
- PEGA 62.30
- Support Level
- NUVL $84.64
- PEGA $94.38
- Resistance Level
- NUVL $89.31
- PEGA $97.31
- Average True Range (ATR)
- NUVL 2.82
- PEGA 2.15
- MACD
- NUVL -0.72
- PEGA -0.47
- Stochastic Oscillator
- NUVL 20.93
- PEGA 70.34
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management, or BPM, with customer relationship management, or CRM, applications. The company focuses on enterprise-size customers, specifically within the financial, insurance, and healthcare fields.